Literature DB >> 23436932

Circulating monocytes are reduced by sphingosine-1-phosphate receptor modulators independently of S1P3.

Nuruddeen D Lewis1, Sokol A Haxhinasto, Shawn M Anderson, Dimitria E Stefanopoulos, Steven E Fogal, Prathima Adusumalli, Sudha N Desai, Lori A Patnaude, Susan M Lukas, Kelli R Ryan, Anthony J Slavin, Maryanne L Brown, Louise K Modis.   

Abstract

Sphingosine-1-phosphate (S1P) receptors are critical for lymphocyte egress from secondary lymphoid organs, and S1P receptor modulators suppress lymphocyte circulation. However, the role of S1P receptors on monocytes is less clear. To elucidate this, we systematically evaluated monocytes in rats and mice, both in naive and inflammatory conditions, with S1P receptor modulators FTY720 and BAF312. We demonstrate that S1P receptor modulators reduce circulating monocytes in a similar time course as lymphocytes. Furthermore, total monocyte numbers were increased in the spleen and bone marrow, suggesting that S1P receptor modulation restricts egress from hematopoietic organs. Monocytes treated ex vivo with FTY720 had reduced CD40 expression and TNF-α production, suggesting a direct effect on monocyte activation. Similar reductions in protein expression and cytokine production were also found in vivo. Suppression of experimental autoimmune encephalomyelitis in mice and rats by FTY720 correlated with reduced numbers of lymphocytes and monocytes. These effects on monocytes were independent of S1P3, as treatment with BAF312, a S1P1,4,5 modulator, led to similar results. These data reveal a novel role for S1P receptors on monocytes and offer additional insights on the mechanism of action of S1P receptor modulators in disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23436932     DOI: 10.4049/jimmunol.1201810

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  28 in total

1.  FTY720 inhibits tubulointerstitial inflammation in albumin overload-induced nephropathy of rats via the Sphk1 pathway.

Authors:  Min Xu; Dan Liu; Li-hong Ding; Kun-ling Ma; Min Wu; Lin-li Lv; Yi Wen; Hong Liu; Ri-ning Tang; Bi-cheng Liu
Journal:  Acta Pharmacol Sin       Date:  2014-11-17       Impact factor: 6.150

Review 2.  Nonclassical patrolling monocyte function in the vasculature.

Authors:  Graham Thomas; Robert Tacke; Catherine C Hedrick; Richard N Hanna
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-04-02       Impact factor: 8.311

Review 3.  The emerging alliance of sphingosine-1-phosphate signalling and immune cells: from basic mechanisms to implications in hypertension.

Authors:  Nicholas Don-Doncow; Yun Zhang; Hana Matuskova; Anja Meissner
Journal:  Br J Pharmacol       Date:  2018-07-03       Impact factor: 8.739

4.  Sphingosine-1-phosphate receptor 1 mediates elevated IL-6 signaling to promote chronic inflammation and multitissue damage in sickle cell disease.

Authors:  Shushan Zhao; Morayo G Adebiyi; Yujin Zhang; Jacob P Couturier; Xuegong Fan; Hongqi Zhang; Rodney E Kellems; Dorothy E Lewis; Yang Xia
Journal:  FASEB J       Date:  2018-01-17       Impact factor: 5.191

Review 5.  An update on the biology of sphingosine 1-phosphate receptors.

Authors:  Victoria A Blaho; Timothy Hla
Journal:  J Lipid Res       Date:  2014-01-23       Impact factor: 5.922

Review 6.  Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy.

Authors:  Richard L Proia; Timothy Hla
Journal:  J Clin Invest       Date:  2015-04-01       Impact factor: 14.808

7.  Engineering in vivo gradients of sphingosine-1-phosphate receptor ligands for localized microvascular remodeling and inflammatory cell positioning.

Authors:  Molly E Ogle; Lauren S Sefcik; Anthony O Awojoodu; Nathan F Chiappa; Kevin Lynch; Shayn Peirce-Cottler; Edward A Botchwey
Journal:  Acta Biomater       Date:  2014-08-13       Impact factor: 8.947

Review 8.  Myeloid cells - targets of medication in multiple sclerosis.

Authors:  Manoj K Mishra; V Wee Yong
Journal:  Nat Rev Neurol       Date:  2016-08-12       Impact factor: 42.937

Review 9.  The sphingosine-1-phosphate receptor: A novel therapeutic target for multiple sclerosis and other autoimmune diseases.

Authors:  Yang Mao-Draayer; Jeffrey Sarazin; David Fox; Elena Schiopu
Journal:  Clin Immunol       Date:  2016-11-23       Impact factor: 3.969

10.  Functional antagonism of sphingosine-1-phosphate receptor 1 prevents cuprizone-induced demyelination.

Authors:  SunJa Kim; Jacek Bielawski; Hyunmin Yang; Yu Kong; Beiyan Zhou; Jianrong Li
Journal:  Glia       Date:  2017-11-29       Impact factor: 7.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.